Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | HNF4A | P41235 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907573 | 0.86 | UGCG (0.46) | UGCGL3MBTL1POLBAPEX1TDP1 | |
| SCHEMBL29907586 | 0.81 | UGCG (0.53) | UGCGDGAT1 | |
| SCHEMBL29907446 | 0.80 | UGCG (0.71) | UGCGHCRTR2HCRTR1 | |
| SCHEMBL29907518 | 0.77 | UGCG (0.53) | UGCG | |
| SCHEMBL29602034 | 0.77 | UGCG (0.55) | UGCG | |
| SCHEMBL29907607 | 0.75 | UGCG (0.48) | UGCGL3MBTL1POLBAPEX1TDP1 | |
| SCHEMBL29907341 | 0.74 | UGCG (0.52) | UGCG | |
| SCHEMBL29907649 | 0.71 | UGCG (0.42) | UGCGL3MBTL1POLBHCRTR2HCRTR1 | |
| SCHEMBL456915 | 0.70 | NAPRT (0.50) | L3MBTL1TDP1NAPRTHCRTR2HCRTR1 | |
| SCHEMBL30919007 | 0.70 | NAPRT (0.50) | L3MBTL1TDP1NAPRTHCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885L3MBTL1 1929/4885POLB 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.